Transgene Biotek share news, announcements and annual reports
BSE: 526139Healthcare ServicesSmall Cap
Transgene Biotek Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993
Last close ₹2.42up ₹0.06 (2.54%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹2.36.
29 Oct: open ₹2.41, high ₹2.68, low ₹2.26
52-week range of traded prices to 29 Oct 2026
₹1.83Low, 4 Feb 2026₹4.27High, 29 Oct 2025
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.19
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 61,658
Transgene Biotek board and management
10 filed, newest first.
Oct 2026
Sep 2026
Dec 2024
31 Dec · Management
Jan 2020
22 Jan · Management
Nov 2019
12 Nov · Management
May 2019
29 May · Management
29 May · Management
Jan 2015
12 Jan · Management
Company is in the process of appointing a Compliance officer for the Company following the resignation of Ms. Srujana And it's Acceptance.
Dec 2012
12 Dec · Management
Following Director has resigned from the Board of Directors of the Company w.e.f. December 02, 2012. - Narayana Murthy Pentyala